Childhood cancer survivors: The integral role of the cardiologist and cardiovascular imaging - 16/08/20
, Jonathan H Soslow, MD, MSCI b, Justin Godown, MD b, Marcus F Stoddard, MD c, Evan C Osmundson, MD, PhD d, Carrie G Lenneman, MD, MSCI e, Debra L Friedman, MD f, Scott C Borinstein, MD, PhD fAbstract |
Importance |
With 80% of childhood cancer survivors (CCS) alive 30 years after diagnosis, preventable causes of death, such as cardiovascular disease resulting from initial cancer therapy, becomes an important metric. This leads to a more pronounced role for cardiologists in the care of CCS.
Observations |
While routine cardiovascular screening has been traditionally performed by the hematologist/oncologist or primary care provider, our understanding of cardiovascular disease in CCS has advanced. The measurement of left ventricular ejection fraction (LVEF) can now be complemented with additional assessments of strain, LV mass, right ventricular function, diastolic function, valve function, the pericardium, coronary perfusion, and biomarkers. Risk factor modification, prophylaxis, and timing of treatment are also critical.
Conclusions and Relevance |
Early cardiovascular screening and treatment in asymptomatic CCS can be nuanced and complex. As a result, there is a renewed opportunity for the cardiologist to play an integral role in the care of CCS.
Key Points |
Question/Purpose: Review cardiovascular disease and the role of the cardiologist in the care of asymptomatic childhood cancer survivors (CCS).
Findings: Cardiovascular care in CCS benefits from a multi-faceted approach that does not overly rely on LVEF.
Meaning: Adequate screening and treatment of cardiovascular disease in asymptomatic CCS may often be optimized by the involvement of a cardiologist.
Il testo completo di questo articolo è disponibile in PDF.Mappa
| Funding Sources: Research reported in this publication is supported by a To-morrow’s Research Fund St. Baldrick’s Scholar Award (Award Number 636214). The content is solely the responsibility of the authors and does not necessarily represent the official views of St. Baldricks. Disclosures: The authors report no conflicts of interest. "The authors are solely responsible for drafting and editing of the paper and its final contents." |
Vol 226
P. 127-139 - Agosto 2020 Ritorno al numero
Articolo precedente
- Cardiovascular implications of idiopathic pulmonary fibrosis: A way forward together?
- Christopher L. Mosher, Robert J. Mentz
- Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial
- Renato D. Lopes, Ariane Vieira Scarlatelli Macedo, Pedro Gabriel Melo de Barros e Silva, Renata Junqueira Moll-Bernardes, Andre Feldman, Guilherme D'Andréa Saba Arruda, Andrea Silvestre de Souza, Denilson Campos de Albuquerque, Lilian Mazza, Mayara Fraga Santos, Natalia Zerbinatti Salvador, C. Michael Gibson, Christopher B. Granger, John H. Alexander, Olga Ferreira de Souza, BRACE CORONA investigators
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?